Preclinical data support that palbociclib can overcome the resistance to EGFR-TKIs in EGFR-mutant NSCLC cell lines via genetic silencing of Snail or the downregulation of its expression [116]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.